Vulcano T, Abdulahad W, van Meurs M, Jongman R, Struys M, Bosch D
Int J Mol Sci. 2024; 25(20).
PMID: 39456827
PMC: 11507532.
DOI: 10.3390/ijms252011045.
Schreiber M, Machacek T, Vajs V, Smidova B, Majer M, Hrdy J
Front Immunol. 2024; 15:1376907.
PMID: 38571957
PMC: 10987685.
DOI: 10.3389/fimmu.2024.1376907.
Schreiber M, Vajs V, Horak P
PeerJ. 2024; 12:e17196.
PMID: 38563013
PMC: 10984186.
DOI: 10.7717/peerj.17196.
Wang F, Zhang G, Xu T, Ma J, Wang J, Liu S
J Exp Clin Cancer Res. 2024; 43(1):24.
PMID: 38245792
PMC: 10799482.
DOI: 10.1186/s13046-024-02955-7.
Yang L, Zhuang L, Ye Z, Li L, Guan J, Gong W
iScience. 2023; 26(10):107881.
PMID: 37841590
PMC: 10570004.
DOI: 10.1016/j.isci.2023.107881.
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario.
Claudia Spagnolo C, Giuffrida G, Cannavo S, Franchina T, Silvestris N, Ruggeri R
Cancers (Basel). 2023; 15(1).
PMID: 36612243
PMC: 9818218.
DOI: 10.3390/cancers15010246.
Advances in the Lung Cancer Immunotherapy Approaches.
Padinharayil H, Alappat R, Joy L, Anilkumar K, Wilson C, George A
Vaccines (Basel). 2022; 10(11).
PMID: 36423060
PMC: 9693102.
DOI: 10.3390/vaccines10111963.
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A, Watkins R, Vilgelm A
Front Immunol. 2021; 12:690499.
PMID: 34140957
PMC: 8204054.
DOI: 10.3389/fimmu.2021.690499.
TNFR2: Role in Cancer Immunology and Immunotherapy.
Yang Y, Islam M, Hu Y, Chen X
Immunotargets Ther. 2021; 10:103-122.
PMID: 33907692
PMC: 8071081.
DOI: 10.2147/ITT.S255224.
Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment.
Tubin S, Khan M, Gupta S, Jeremic B
Cancers (Basel). 2021; 13(4).
PMID: 33673332
PMC: 7918834.
DOI: 10.3390/cancers13040775.
NEUTROPHIL/LYMPHOCYTE RATIO AND PLATELET/LYMPHOCYTE RATIO IN PATIENTS WITH NSCLC.
Cukic V
Mater Sociomed. 2016; 28(5):378-381.
PMID: 27999489
PMC: 5149430.
DOI: 10.5455/msm.2016.28.378-381.
Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M, Paiva-Oliveira D, Parada B, Alves V, Sousa V, Chijioke O
BMC Med. 2016; 14(1):163.
PMID: 27769244
PMC: 5075212.
DOI: 10.1186/s12916-016-0715-2.
Highly efficient IL-21 and feeder cell-driven expansion of human NK cells with therapeutic activity in a xenograft mouse model of melanoma.
Granzin M, Stojanovic A, Miller M, Childs R, Huppert V, Cerwenka A
Oncoimmunology. 2016; 5(9):e1219007.
PMID: 27757317
PMC: 5048763.
DOI: 10.1080/2162402X.2016.1219007.
Super natural killer cells that target metastases in the tumor draining lymph nodes.
Chandrasekaran S, Chan M, Li J, King M
Biomaterials. 2015; 77:66-76.
PMID: 26584347
PMC: 4684422.
DOI: 10.1016/j.biomaterials.2015.11.001.
Improved Chemotherapeutic Activity by Morus alba Fruits through Immune Response of Toll-Like Receptor 4.
Chang B, Kim S, Lee M, Park H, Kim S
Int J Mol Sci. 2015; 16(10):24139-58.
PMID: 26473845
PMC: 4632743.
DOI: 10.3390/ijms161024139.
The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention.
Domagala-Kulawik J
Transl Lung Cancer Res. 2015; 4(2):177-90.
PMID: 25870800
PMC: 4384216.
DOI: 10.3978/j.issn.2218-6751.2015.01.11.
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis.
Liu G, Lu S, Wang X, Page S, Higano C, Plymate S
J Clin Invest. 2013; 123(10):4410-22.
PMID: 24018560
PMC: 3784540.
DOI: 10.1172/JCI69369.